Image-Guided Robotic Radiosurgery for the Management of Spinal Ependymomas.
CyberKnife
SBRT
ependymal tumors
ependymoma
radiosurgery
spine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
01
2021
accepted:
25
03
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Ependymomas are rare neoplasms of the central nervous system (CNS), usually localized intracranially and most commonly diagnosed in children. Spinal ependymomas are more frequent in young adults. They are either primary lesions or manifest as disseminated seeding of cranial tumors. Data on the management of spinal ependymoma lesions remain scarce, especially concerning stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The purpose of this study is to report the treatment outcomes of two institutions using robotic radiosurgery (RRS) for the treatment of spinal ependymomas. All patients with a histopathologically confirmed diagnosis of an ependymoma WHO grade II or III who were treated with RRS for one or more spinal lesions were included in this analysis. Twelve patients underwent RRS for the treatment of 32 spinal ependymoma lesions between 2005 and 2020. Two patients were below the age of 18 when treated, whereas nine patients (75%) suffered from a primary spinal ependymoma. The median dose was 15 Gy prescribed to a median isodose of 70%, with 27 lesions (84%) receiving a single-session treatment. The local control (LC) after a median follow-up of 56.7 months was 84%. LC rates at 1, 3, and 5 years were 92, 85, and 77%, respectively. The Kaplan-Meier estimated overall survival after 1, 3, and 5 years were 75, 75, and 64%, respectively. Five patients died, all of them suffering from an anaplastic ependymoma, with widespread CNS tumor progression being the reason for death in four patients. The majority of patients (58%) showed a stable neurological status at the last available follow-up. Overall, the treatment was well tolerated. RRS appears to be a safe and efficient treatment modality for managing primary and secondary spinal ependymal tumors in patients with multiple lesions and local recurrences.
Sections du résumé
BACKGROUND
BACKGROUND
Ependymomas are rare neoplasms of the central nervous system (CNS), usually localized intracranially and most commonly diagnosed in children. Spinal ependymomas are more frequent in young adults. They are either primary lesions or manifest as disseminated seeding of cranial tumors. Data on the management of spinal ependymoma lesions remain scarce, especially concerning stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The purpose of this study is to report the treatment outcomes of two institutions using robotic radiosurgery (RRS) for the treatment of spinal ependymomas.
MATERIALS AND METHODS
METHODS
All patients with a histopathologically confirmed diagnosis of an ependymoma WHO grade II or III who were treated with RRS for one or more spinal lesions were included in this analysis.
RESULTS
RESULTS
Twelve patients underwent RRS for the treatment of 32 spinal ependymoma lesions between 2005 and 2020. Two patients were below the age of 18 when treated, whereas nine patients (75%) suffered from a primary spinal ependymoma. The median dose was 15 Gy prescribed to a median isodose of 70%, with 27 lesions (84%) receiving a single-session treatment. The local control (LC) after a median follow-up of 56.7 months was 84%. LC rates at 1, 3, and 5 years were 92, 85, and 77%, respectively. The Kaplan-Meier estimated overall survival after 1, 3, and 5 years were 75, 75, and 64%, respectively. Five patients died, all of them suffering from an anaplastic ependymoma, with widespread CNS tumor progression being the reason for death in four patients. The majority of patients (58%) showed a stable neurological status at the last available follow-up. Overall, the treatment was well tolerated.
CONCLUSION
CONCLUSIONS
RRS appears to be a safe and efficient treatment modality for managing primary and secondary spinal ependymal tumors in patients with multiple lesions and local recurrences.
Identifiants
pubmed: 33996577
doi: 10.3389/fonc.2021.654251
pmc: PMC8117154
doi:
Types de publication
Journal Article
Langues
eng
Pagination
654251Informations de copyright
Copyright © 2021 Ehret, Kufeld, Fürweger, Haidenberger, Windisch, Senger, Kord, Träger, Kaul, Schichor, Tonn and Muacevic.
Déclaration de conflit d'intérêts
FE reports a grant from Ludwig-Maximilians-University Munich and honoraria from Accuray outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):634-641
pubmed: 29280457
Cancer. 2000 Feb 15;88(4):870-5
pubmed: 10679657
Br J Cancer. 2013 Jun 11;108(11):2367-71
pubmed: 23660944
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97
pubmed: 18406885
J Neurooncol. 2004 Jan;66(1-2):187-90
pubmed: 15015785
Acta Neuropathol. 2017 Jan;133(1):5-12
pubmed: 27858204
Stereotact Funct Neurosurg. 2019;97(3):189-194
pubmed: 31590165
Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41
pubmed: 8892469
Neuro Oncol. 2018 Mar 27;20(4):445-456
pubmed: 29194500
World Neurosurg. 2018 Mar;111:e53-e61
pubmed: 29225135
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):929-35
pubmed: 11429220
Radiother Oncol. 1997 Jun;43(3):269-73
pubmed: 9215786
J Neurooncol. 2006 Aug;79(1):51-6
pubmed: 16557349
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Handb Clin Neurol. 2016;134:417-31
pubmed: 26948369
Neurosurgery. 2019 Jan 1;84(1):227-234
pubmed: 29608701
J Surg Res. 2009 Oct;156(2):340-51
pubmed: 19577759
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
J Neurosurg Pediatr. 2010 Nov;6(5):417-23
pubmed: 21039163
J Neurooncol. 2012 Jul;108(3):507-12
pubmed: 22437346
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1541-8
pubmed: 22245198
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Neurosurg Focus. 2003 Nov 15;15(5):E10
pubmed: 15323467
Childs Nerv Syst. 2009 Oct;25(10):1269-73
pubmed: 19357854
Neuro Oncol. 2018 Nov 12;20(12):1616-1624
pubmed: 30053291
J Neurooncol. 2014 Jan;116(1):107-11
pubmed: 24078173
Front Oncol. 2020 Jun 09;10:907
pubmed: 32582555